Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 11/20 | 0.72 |
| ▸ | ICMT | O60725 | 5/20 | 0.41 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.36 |
| ▸ | AKT1 | P31749 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437352 | 0.94 | MDM2 (0.68) | MDM2ICMTCNR1 | |
| SCHEMBL1437553 | 0.94 | MDM2 (0.71) | MDM2ICMTPIK3R2RPS6KB1AKT1 | |
| SCHEMBL1437197 | 0.90 | MDM2 (0.58) | MDM2ICMT | |
| SCHEMBL1437417 | 0.89 | MDM2 (0.64) | MDM2ICMTPIK3R2RPS6KB1AKT1 | |
| SCHEMBL1438326 | 0.88 | MDM2 (0.67) | MDM2PIK3R2RPS6KB1AKT1 | |
| SCHEMBL1437475 | 0.87 | MDM2 (0.71) | MDM2ICMTPIK3R2RPS6KB1AKT1 | |
| SCHEMBL1437386 | 0.87 | MDM2 (0.70) | MDM2CNR1 | |
| SCHEMBL9893830 | 0.87 | MDM2 (0.75) | MDM2PIK3R2CNR1 | |
| SCHEMBL1437212 | 0.84 | MDM2 (1.00) | MDM2PIK3R2RPS6KB1AKT1 | |
| SCHEMBL9893654 | 0.83 | MDM2 (0.65) | MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470502-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
| WO-2011023677-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | MDM2 2/4885ICMT 3800/4885PIK3R2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.